1. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
- Author
-
Goldwirt, Lauriane, Bauer, Rebecca, Liegeon, Geoffroy, Charreau, Isabelle, Delaugerre, Constance, Cotte, Laurent, Pialou, Gilles, Cua, Eric, Laghzal, Aïcha, Buschman, Lane, Anderson, Peter L, Mourah, Samia, Meyer, Laurence, Molina, Jean-Michel, Group, the ANRS IPERGAY Study, ANRS IPERGAY Study Group, and Anderson, Peter
- Subjects
- *
HUMAN sexuality , *PILLS , *SEXUAL intercourse , *PRE-exposure prophylaxis , *RANK correlation (Statistics) , *BLOOD coagulation factor VIII , *HIV prevention , *ANTI-HIV agents , *HIV infections , *RESEARCH , *ORGANOPHOSPHORUS compounds , *PURINES , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *PREVENTIVE health services , *HOMOSEXUALITY , *COMPARATIVE studies , *DRUGS , *RESEARCH funding , *PATIENT compliance - Abstract
Background: Tenofovir diphosphate (TFV-DP) concentration in dried blood spots (DBSs) is a reliable pharmacokinetics biomarker of adherence to tenofovir disoproxil fumarate (TDF). We aimed to use DBSs to estimate pill intake among participants using on-demand pre-exposure prophylaxis (PrEP) and to identify predictive factors associated with higher TFV-DP concentrations.Methods: DBSs were collected at the last study visit of the open-label phase of the ANRS IPERGAY study, assessing on-demand oral TDF/emtricitabine for PrEP among MSM and transgender female participants. We quantified TFV-DP in DBSs centrally. We assessed correlation between pill count and TFV-DP concentration by Spearman correlation and explored associations between participant demographics, sexual behaviour and PrEP use during sexual intercourse (SI) with TFV-DP concentrations by univariate and multivariate logistic regression models.Results: The median age of the 245 participants included in this study was 40 years, with a median body weight of 73 kg. Median (IQR) TFV-DP concentration reached 517 (128-868) fmol/punch, corresponding to an estimated intake of 8-12 tablets per month (2-3 doses per week). Only 39% of participants had a TFV-DP concentration above 700 fmol/punch. TFV-DP concentrations were moderately correlated with pill count (r: 0.59; P < 0.001). In multivariate analysis, only systematic use of PrEP during SI and more frequent episodes of SI in the past 4 weeks were significantly associated with higher TFV-DP levels [OR (95% CI): 11.30 (3.62-35.33) and 1.46 (1.19-1.79), respectively; P < 0.001].Conclusions: Among participants using on-demand PrEP, estimated pill intake reached 8-12 tablets per month and was correlated with frequency and systematic use of PrEP for SI. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF